Celltrion Launches AVTOZMA® Subcutaneous Formulation for U.S. Patients Celltrion has officially launched the AVTOZMA® (tocilizumab-anoh) subcutaneous formulation in the U.S., offering new treatment options for chronic inflammatory diseases.

Celltrion Launches AVTOZMA® Subcutaneous Formulation for U.S. Patients #United_States #Incheon #Celltrion #AVTOZMA #tocilizumab-anoh

Weekly Roundup - PHARMA - 10 February 2025 🔊Celltrion’s Avtozma Wins FDA Approval for Autoimmune & Inflammatory Diseases Avtozma, an Actemra biosimilar, is approved in both IV and SC forms, backed by a Phase III trial confirming its similarity...

Weekly Roundup - PHARMA - 10 February 2025

www.linkedin.com/pulse/weekly...

kstrategyand.com/pharma-news

#Celltrion #Avtozma #Axsome #Symbravo #Anzupgo #PharmaNews #Biotech #Pharma #Healthcare #ClinicalTrials #Humanteconomy #Humantec #KStrategyand

FDA Greenlights Celltrion’s AVTOZMA®, A Biosimilar to ACTEMRA® for Multiple Conditions Celltrion's AVTOZMA® has received FDA approval as a biosimilar to ACTEMRA®, expanding treatment options for various conditions including rheumatoid arthritis.

FDA Greenlights Celltrion’s AVTOZMA®, A Biosimilar to ACTEMRA® for Multiple Conditions #USA #FDA #Jersey_City #Celltrion #AVTOZMA